Migraine Patients to Wait for Triptan Alternative

Scandinavian researchers writing in The Lancet gave a warm review to an investigational drug for migraine, but patients in the United States, at least, will have a wait before it reaches them. Merck manufactures the drug, called telcagepant, and was initially expected to seek approval from the U.S. Food and Drug Administration last year. An online Lancet review by researchers from Sweden and Norway touted telcagepant as holding out hope for migraine patients with acute attacks that fail to...Full Story
Commenting on this article is closed.